ATE294504T1 - Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen - Google Patents

Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen

Info

Publication number
ATE294504T1
ATE294504T1 AT99968523T AT99968523T ATE294504T1 AT E294504 T1 ATE294504 T1 AT E294504T1 AT 99968523 T AT99968523 T AT 99968523T AT 99968523 T AT99968523 T AT 99968523T AT E294504 T1 ATE294504 T1 AT E294504T1
Authority
AT
Austria
Prior art keywords
compositions
methods
cell proliferation
beta
inhibiting
Prior art date
Application number
AT99968523T
Other languages
English (en)
Inventor
John N Vournakis
Sergio Finkielsztein
Ernest R Pariser
Original Assignee
Marinepolymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinepolymer Tech Inc filed Critical Marinepolymer Tech Inc
Application granted granted Critical
Publication of ATE294504T1 publication Critical patent/ATE294504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT99968523T 1998-12-22 1999-12-21 Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen ATE294504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/218,288 US6063911A (en) 1993-12-01 1998-12-22 Methods and compositions for treatment of cell proliferative disorders
PCT/US1999/030575 WO2000036918A1 (en) 1998-12-22 1999-12-21 Methods and compositions for treatment of cell proliferative disorders

Publications (1)

Publication Number Publication Date
ATE294504T1 true ATE294504T1 (de) 2005-05-15

Family

ID=22814511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968523T ATE294504T1 (de) 1998-12-22 1999-12-21 Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen

Country Status (14)

Country Link
US (1) US6063911A (de)
EP (1) EP1139752B1 (de)
JP (1) JP4795539B2 (de)
CN (1) CN100488512C (de)
AT (1) ATE294504T1 (de)
AU (1) AU780248B2 (de)
CA (1) CA2356087C (de)
DE (1) DE69925156T2 (de)
ES (1) ES2242448T3 (de)
HK (1) HK1043507B (de)
IL (2) IL143700A0 (de)
NO (1) NO330033B1 (de)
NZ (1) NZ512586A (de)
WO (1) WO2000036918A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US7566452B1 (en) * 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
MXPA02006461A (es) 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
HRP20030124A2 (en) * 2000-08-22 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
US7041657B2 (en) * 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
WO2004060172A1 (en) 2002-12-31 2004-07-22 Marine Polymer Technologies, Inc. Hemostatic compositions and uses therefor
JP2006516571A (ja) * 2003-01-17 2006-07-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 良性前立腺増殖症の処置
JP5028086B2 (ja) * 2003-02-24 2012-09-19 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞−ポリマー繊維組成物及びその使用
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
NZ546204A (en) 2003-09-12 2009-12-24 Marinepolymer Tech Inc Vascular access preservation in haemodialysis patients
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US20080166323A1 (en) * 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
EP3263581B2 (de) 2005-05-17 2025-07-09 University of Connecticut Zusammensetzungen und verfahren zur immunmodulation in einem organismus
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
AU2008219065B2 (en) * 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
NZ599338A (en) * 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
EP2224961A1 (de) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen
ES2598005T3 (es) 2009-08-14 2017-01-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
GB201616087D0 (en) * 2016-09-21 2016-11-02 Tomalgae Cvba Algae comprising therapeutic and/or nutritional agents
US12239720B2 (en) 2018-04-06 2025-03-04 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) * 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3989535A (en) * 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US3988411A (en) * 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
JPS55152705A (en) * 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
US4378017A (en) * 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
US4803168A (en) * 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) * 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
IL80032A (en) * 1985-09-23 1992-07-15 Lilly Co Eli Anti-tumor phenyl-aminocarbonylsulfonamides,their preparation and pharmaceutical compositions containing them
JPS62288602A (ja) * 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
US4942129A (en) * 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5071977A (en) * 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
US5116747A (en) * 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
US5229123A (en) * 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5219749A (en) * 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
EP0610441A4 (de) * 1991-10-29 1996-01-10 Clover Cons Ltd Vernetzbare polysacchariden, polykationen und lipiden verwendbar zum einkapseln und abgabe von arzneimitteln.
HUT67665A (en) * 1991-11-05 1995-04-28 Smithkline Beckman Corp Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
IL100096A (en) * 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5624679A (en) * 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (de) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1996039122A1 (en) * 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
US5998468A (en) * 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
WO1997037987A1 (en) * 1996-04-10 1997-10-16 Warner-Lambert Company Ketoacid endothelin antagonists

Also Published As

Publication number Publication date
ES2242448T3 (es) 2005-11-01
AU780248B2 (en) 2005-03-10
NZ512586A (en) 2004-01-30
AU2591900A (en) 2000-07-12
HK1043507B (zh) 2009-12-24
NO20013071L (no) 2001-08-20
NO20013071D0 (no) 2001-06-20
DE69925156T2 (de) 2006-02-16
WO2000036918A1 (en) 2000-06-29
CN1335749A (zh) 2002-02-13
US6063911A (en) 2000-05-16
JP4795539B2 (ja) 2011-10-19
EP1139752A1 (de) 2001-10-10
DE69925156D1 (de) 2005-06-09
CA2356087C (en) 2009-02-17
CA2356087A1 (en) 2000-06-29
IL143700A0 (en) 2002-04-21
NO330033B1 (no) 2011-02-07
IL143700A (en) 2006-08-01
EP1139752A4 (de) 2003-01-02
EP1139752B1 (de) 2005-05-04
WO2000036918A9 (en) 2000-11-23
JP2003522732A (ja) 2003-07-29
CN100488512C (zh) 2009-05-20
HK1043507A1 (zh) 2002-09-20

Similar Documents

Publication Publication Date Title
ATE294504T1 (de) Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
ATE256698T1 (de) Biologisch aktive peptide und ihre zubereitungen und verwendungen
BR0211199A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
GB9924957D0 (en) Novel treatment
DE69901569D1 (de) Humane antikörper gegen faktor ix/ixa
ID25509A (id) Anti pembekuan protein
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
AU4653301A (en) Anti-freeze proteins, their production and use
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE250427T1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
DE69728415D1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
CA2318432A1 (en) The use of isolated domains of type iv collagen to modify cell and tissue interactions
EE200000510A (et) CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
AU2118500A (en) Transcription factor e2f dna-binding domain inhibitor peptides and their use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties